+Compare
ACB
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
179.92M

ACB Price Prediction, Aurora Cannabis AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT May 26, 2023

Momentum Indicator for ACB turns negative, indicating new downward trend

ACB saw its Momentum Indicator move below the 0 level on May 23, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on May 26, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

ACB moved below its 50-day moving average on May 23, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ACB broke above its upper Bollinger Band on May 05, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ACB entered a downward trend on May 17, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ACB's RSI Indicator exited the oversold zone, of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in of 214 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.448) is normal, around the industry mean (41.822). P/E Ratio (0.000) is within average values for comparable stocks, (52.947). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.710). ACB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (0.945) is also within normal values, averaging (55.800).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I. Advisor
published Earnings

ACB is expected to report earnings to rise 315.14% to -9 cents per share on September 26

Aurora Cannabis ACB Stock Earnings Reports
Q1'23
Est.
$-0.09
Q4'22
Beat
by $0.03
Q3'22
Missed
by $0.07
Q2'22
Missed
by $1.86
Q1'22
Missed
by $3.47
The last earnings report on May 11 showed earnings per share of -2 cents, beating the estimate of -5 cents. With 5.60M shares outstanding, the current market capitalization sits at 179.92M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Intra-Cellular Therapies (NASDAQ:ITCI), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.27B. The market cap for tickers in the group ranges from 246 to 77B. MKKGY holds the highest valuation in this group at 77B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 0%. For the same Industry, the average monthly price growth was 42%, and the average quarterly price growth was 55%. VNNYD experienced the highest price growth at 310%, while BLMS experienced the biggest fall at -60%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -45%. For the same stocks of the Industry, the average monthly volume growth was 64% and the average quarterly volume growth was -96%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 72
Price Growth Rating: 65
SMR Rating: 85
Profit Risk Rating: 93
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a licensed producer of medical marijuana in Canada

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
500-10355 Jasper Avenue
Phone
+1 855 279-4652
Employees
1338
Web
https://investor.auroramj.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSGRX40.540.48
+1.20%
Goldman Sachs Equity Income A
SSCPX5.970.07
+1.19%
Saratoga Small Capitalization I
JIECX16.690.19
+1.15%
JPMorgan International Equity C
GGUPX8.790.09
+1.03%
Goldman Sachs Global Rl Estt Secs P
DLDRX46.990.22
+0.47%
BNY Mellon Natural Resources I

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-3.55%
CGC - ACB
77%
Closely correlated
-0.66%
TLRY - ACB
72%
Closely correlated
-21.19%
CRON - ACB
66%
Closely correlated
-1.67%
SNDL - ACB
66%
Loosely correlated
-0.32%
OGI - ACB
66%
Loosely correlated
-0.25%
More